NO177794C - Fremgangsmåte for fremstilling av et fusjonsprotein, samt nukleinsyre, ekspresjonsvektor og vertscelle som kan anvendes ved fremgangsmåten - Google Patents

Fremgangsmåte for fremstilling av et fusjonsprotein, samt nukleinsyre, ekspresjonsvektor og vertscelle som kan anvendes ved fremgangsmåten

Info

Publication number
NO177794C
NO177794C NO882918A NO882918A NO177794C NO 177794 C NO177794 C NO 177794C NO 882918 A NO882918 A NO 882918A NO 882918 A NO882918 A NO 882918A NO 177794 C NO177794 C NO 177794C
Authority
NO
Norway
Prior art keywords
preparation
nucleic acid
well
host cell
fusion protein
Prior art date
Application number
NO882918A
Other languages
English (en)
Norwegian (no)
Other versions
NO177794B (no
NO882918L (no
NO882918D0 (no
Inventor
Alan John Kingsman
Susan Mary Kingsman
Sally Elizabeth Adams
Original Assignee
British Bio Technology
Oxford Gene Systems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868626148A external-priority patent/GB8626148D0/en
Priority claimed from GB878708532A external-priority patent/GB8708532D0/en
Application filed by British Bio Technology, Oxford Gene Systems Ltd filed Critical British Bio Technology
Publication of NO882918D0 publication Critical patent/NO882918D0/no
Publication of NO882918L publication Critical patent/NO882918L/no
Publication of NO177794B publication Critical patent/NO177794B/no
Publication of NO177794C publication Critical patent/NO177794C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO882918A 1986-11-01 1988-06-30 Fremgangsmåte for fremstilling av et fusjonsprotein, samt nukleinsyre, ekspresjonsvektor og vertscelle som kan anvendes ved fremgangsmåten NO177794C (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB868626148A GB8626148D0 (en) 1986-11-01 1986-11-01 Antigen presentation & purification system
GB878708532A GB8708532D0 (en) 1987-04-09 1987-04-09 Particulate hybrid hiv antigens
US3688887A 1987-04-10 1987-04-10
PCT/GB1987/000763 WO1988003562A1 (fr) 1986-11-01 1987-10-28 Particules hybrides antigenes de l'hiv

Publications (4)

Publication Number Publication Date
NO882918D0 NO882918D0 (no) 1988-06-30
NO882918L NO882918L (no) 1988-08-29
NO177794B NO177794B (no) 1995-08-14
NO177794C true NO177794C (no) 1995-11-22

Family

ID=27263195

Family Applications (1)

Application Number Title Priority Date Filing Date
NO882918A NO177794C (no) 1986-11-01 1988-06-30 Fremgangsmåte for fremstilling av et fusjonsprotein, samt nukleinsyre, ekspresjonsvektor og vertscelle som kan anvendes ved fremgangsmåten

Country Status (8)

Country Link
EP (1) EP0329671B1 (fr)
JP (1) JPH02501107A (fr)
AU (1) AU606627B2 (fr)
DE (1) DE3788806T2 (fr)
ES (1) ES2010230A6 (fr)
HU (1) HUT50875A (fr)
NO (1) NO177794C (fr)
WO (1) WO1988003562A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3006789A (en) * 1988-02-24 1989-08-24 Smithkline Beckman Corporation Expression of hiv binding proteins
US5614404A (en) * 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5747324A (en) * 1988-06-10 1998-05-05 Therion Biologics Corporation Self-assembled, defective, non-self-propagating lentivirus particles
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
EP0361749B1 (fr) * 1988-09-27 1995-02-08 Dana Farber Cancer Institute Vecteur contenant un provirus de VIH-I compétent pour la réplication et un gène hétérologue
CA2003383A1 (fr) * 1988-11-23 1990-05-23 Sushil G. Devare Antigenes de hiv recombinants derives d'adn synthetique
JPH04504950A (ja) * 1988-11-23 1992-09-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 位置特異的挿入ベクターおよびこれを用いた方法
ES2198400T3 (es) * 1989-06-01 2004-02-01 Applied Biotechnology, Inc. Vector que codifica particulas virales no autopropagantes, defectuosas, auto-ensambladas.
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US5989886A (en) * 1991-01-02 1999-11-23 The Johns Hopkins University Method for the inhibition and prevention of viral replication using fusions of a virus protein and a destructive enzyme
GB9107631D0 (en) * 1991-04-10 1991-05-29 British Bio Technology Proteinaceous particles
JPH07505412A (ja) * 1992-04-14 1995-06-15 ブリティッシュ　バイオテック　ファーマシューティカルズリミテッド Ｃｔｌ応答の誘導
AU5838794A (en) * 1993-01-16 1994-08-15 British Bio-Technology Limited Hybrid particle-forming protein comprising a particle-inducing segment and a plurality of antigens
FR2703996B1 (fr) * 1993-04-16 1995-07-21 Transgene Sa Ensemble de transposition destine au transfert d'un gene d'interet dans le genome d'une cellule eucaryote.
DE4335025A1 (de) * 1993-10-14 1995-04-20 Boehringer Ingelheim Int Endosomolytisch wirksame Partikel
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
WO1998029551A1 (fr) * 1997-01-02 1998-07-09 Universidade Federal De Minas Gerais PROCEDE POUR L'EXPRESSION ET LA PRODUCTION D'UNE PROTEINE HYBRIDE DE RECOMBINAISON (p24/p17) DERIVEE DU VIRUS DE L'IMMUNODEFICIENCE HUMAINE (HIV-1)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR76274B (fr) * 1981-08-04 1984-08-04 Univ California
WO1988003563A1 (fr) * 1986-11-01 1988-05-19 Oxford Gene Systems Limited Proteines et particules de fusion

Also Published As

Publication number Publication date
DE3788806D1 (de) 1994-02-24
NO177794B (no) 1995-08-14
DE3788806T2 (de) 1994-07-07
WO1988003562A1 (fr) 1988-05-19
NO882918L (no) 1988-08-29
HUT50875A (en) 1990-03-28
AU8153487A (en) 1988-06-01
JPH02501107A (ja) 1990-04-19
EP0329671B1 (fr) 1994-01-12
ES2010230A6 (es) 1989-11-01
NO882918D0 (no) 1988-06-30
AU606627B2 (en) 1991-02-14
EP0329671A1 (fr) 1989-08-30

Similar Documents

Publication Publication Date Title
NO177793C (no) Fremgangsmåte for fremstilling av et fusjonsprotein, samt nukleinsyre, ekspresjonsvektor og vertscelle som kan anvendes ved fremgangsmåten
NO177794C (no) Fremgangsmåte for fremstilling av et fusjonsprotein, samt nukleinsyre, ekspresjonsvektor og vertscelle som kan anvendes ved fremgangsmåten
NO175715C (no) Analogifremgangsmåte ved fremstilling av terapeutisk aktive aminosyrederivater, samt mellomprodukter ved fremstilling av disse
DK247084A (da) 7-amino-1-cyclopropyl-6,8-difluor-1,4-dihydro-4-oxo-3-quinolincarboxylsyrer, fremgangsmaader til deres fremstilling samt antibakterielle midler indeholdende disse
DK110885A (da) Nucleinsyre-proteinkonjugater, disses anvendelse samt fremgangsmaade til fremstilling heraf
NO871785D0 (no) Fremgangsmaate for fremstilling av et proteinprodukt, samt vektorsystem for fremgangsmaatens utfoerelse.
IT7921838A0 (it) Processo di rivelazione e di caratterizzazione di un acido nucleico o di una sua sequenza e reattivo enzimatico per la realizzazione di questo processo.
DK374087D0 (da) Fremgangsmaade til fremstilling af proteiner med faktor viii-aktivitet ved hjaelp af mikrobielle voertsceller og ekspressionsvektorer, vaertsceller og antistoffer til anvendelse ved denne
NO964445D0 (no) DNA-sekvens, vektor, vertscelle og fremgangsmåte for transfeksjon av hematopoeseceller med eksogen DNA
NZ221790A (en) Method for the continuous production of a heterologous protein in a eukaryotic host cell
ATE158816T1 (de) Expression von pace in wirtszellen und verfahren zu dessen verwendung
ES534102A0 (es) Procedimiento para introducir dna en un anfitrion de cepa de microorganismo unicelular
AU587989B2 (en) DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
ZA864525B (en) Vector for expression of interferon-ypsilon in mammalian cells,method for using it and product obtained
DK388789D0 (da) Hybridderivat af humant protein d, dets fremstilling og anvendelse samt dna, som koder derfor, og genstruktur og vaertscelle indeholdende denne dna
IT8520036A0 (it) Processo per la preparazione biotecnologica di acidi alfa-arilalcanoici otticamente attivi.
DK534286A (da) Nicotinsyrederivater, deres fremstilling og anvendelse som herbicider samt mellemprodukter ved fremstillingen og disses fremstilling
DK124787A (da) Peptider indeholdende op til 8-aminosyregrupperinger og fysiologisk uskadelige salte deraf, deres fremstilling og anvendelse som laegemidler samt mellemprodukter ved fremstillingen
NO174167C (no) Fremgangsmåte til fremstilling av mekanisk masse, samt anvendelse av enzymer og/eller kjemikalier ved fremstilling av mekanisk masse
JPS5550892A (en) Protein production * modified dna and vector applicable to said method
DK94385A (da) Proteiner, farmaceutiske praeparater, gener, vektorer, vaertsorganismer samt fremgangsmaader til deres fremstilling
BR9106555A (pt) Proteina,celula hospedeira e processos para a preparacao de uma proteina e de acido nucleico
PT90976A (pt) Processo para a preparacao de proteinas e de acidos nucleicos
AU6521186A (en) Lytic viruses as expression vectors, host cell containing same and process for protein production
NO874573D0 (no) Nucleinsyreprober for paavisning av latent humant cytomegalovirus i lodprodukter.